Answers are grounded in this paper and cite their sources.
Early gadolinium enhancement (EGE) can serve as a practical alternative to T2 mapping for identifying acute myocarditis in facilities where T2 mapping is unavailable.
Sir, We are delighted that Dr Adam Ioannou has written to us with a comment on our report about myocarditis after coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines.1 Dr Adam pointed out that T2 mapping can be used to discriminate whether it is due to acute or chronic myocarditis. Because T1 mapping, extracellular volume (ECV) and late gadolinium enhancement (LGE) could reflect previous myocardial injury and residual scar, in addition to acute myocardial injury. We agree that T2 mapping is useful for myocardial edema including acute myocarditis;2 unfortunately, T2 mapping could not be performed in our case. However, it is also worth mentioning that even with T2 mapping, it is not easy to distinguish between the acute and chronic phases, and there are few facilities where T2 mapping is possible. Therefore, we would also like to mention the usefulness of early gadolinium enhancement (EGE). Reportedly, EGE can be performed at any facility, and it is also useful for hyperemia with myocarditis.3,4 It has recently been reported that all patients with myocarditis after a COVID-19 mRNA vaccine showed EGE findings.5 Our case also showed EGE findings in the region consistent with LGE. Since the possible modality is different for each facility, we emphasize the importance of conducting appropriate tests according to the facility’s capabilities.
No takes yet. Share an insight, caveat, or question.
Awaya et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: